



## Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

September 22, 2021

NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference being held virtually September 27-30, 2021.

Additional details can be found below:

**Date:** Thursday, September 30, 2021

**Time:** 10:00 a.m. ET

**Location:** [Webcast Link](#) – or at the company's website ( [click here](#) )

A replay of the presentation will be available by visiting the "[Events & Presentations](#)" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

### **About Rain Therapeutics Inc.**

Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

### **Media Contact**

Jordyn Temperato

LifeSci Communications

+1.646.876.5196

[jtemperato@lifescicomms.com](mailto:jtemperato@lifescicomms.com)